Normal Track versus Fast-Track for Medical Device Registration in Egypt

1. Key takeaways

At the level of the guide, Egypt provides two parallel pathways for medical device registration: the normal track and the fast-track. The difference lies not in the technical threshold but in queueing priority and the length of the clocks: the normal track is ordered by a waiting list, while the fast-track does not enter the waiting queue and receives priority review. The corresponding official timings are as follows. For acceptance, 5 working days on the normal track and 3 working days on the fast track. For the assessment that issues correction requests, 20 working days on the normal track and 7 working days on the fast track. What the company pays for is the price of priority, and what it buys in return is certainty of timing.

2. Legal basis

3. Expert insights

Insight one: the fast-track buys an exit from the queue, not an exemption from review.

The guide states two sets of days, normal and fast, at both the acceptance stage and the assessment stage, but the technical checklist for the two pathways is identical. What the fast-track shortens is the internal response and assessment timing on the EDA side; the company’s documentary obligations are not reduced by a single item. The most common misjudgment among applicants is to read the fast-track as an invitation to submit less material. In practice, every document that would be required on the normal track remains required on the fast-track, and a file that is thinner than the published checklist will simply be suspended for correction like any other.

Insight two: the two sets of timings cover both registration and changes, and the ratio is stable.

For registration, the pairs are 5/3 and 20/7 working days. For changes, Section 5.2 of GL.CAMD.003 sets 25/10 working days. In both scenarios the fast-track clock amounts to roughly 40% to 60% of the normal-track clock, and that proportion can be used as a stable coefficient when modeling project schedules. Because the same ratio holds across two different regulatory scenarios, it behaves less like an accident of drafting and more like a deliberate policy of prioritization, which makes it defensible to use it in forward planning.

Insight three: the existence of a waiting list means the nominal days of the normal track are not the actual days.

The guide describes the normal track as ordered according to the waiting list. The length of that list is determined by the volume of applications under review at any given time, which is a variable outside the applicant’s control. For projects with a committed market-entry date, such as tenders already awarded under the Unified Procurement Authority, AUPP, or hospital procurement tenders, the variance risk of the normal track is significantly higher than that of the fast-track. A schedule built on nominal days alone will systematically understate the exposure for such projects.

Insight four: the value of the fast-track is even more visible around the lapse gates.

Section 4.1.1 provides that a suspension for correction may last at most 90 working days, after which the application is deemed withdrawn. On the change side, the rules provide that where the company fails to follow up within 60 working days, the file is archived and the grace period is suspended. These gates run on working days rather than calendar days, and they are not affected by the choice of track. The fast-track compresses the response segments that come before them; the gate segments still depend entirely on the company’s own cadence of preparation and follow-up.

Insight five: the choice of track should be moved forward into the quotation and contracting stage.

Service fees are charged according to decisions issued by the Chairman of the EDA, and the fee categories follow the Prime Minister’s Decision No. 777/2020. The fee differential between the two tracks should therefore be a foreseeable contractual term. (Practical estimate: the specific amounts must follow the payment notice on the MeDevice platform and the EDA Chairman’s decisions in force at the time; this article does not list specific figures.) Locking the track and the payer of the fees into the contract prevents the situation where the track is switched hastily at the acceptance stage, with the associated timing assumptions invalidated mid-project.

4. Practical recommendations

1. Select the track by project profile: projects with a firm market-entry date or a tender delivery milestone should take the fast-track; routine line extensions and stock-coverage projects can take the normal track.
2. Write the waiting-list risk into the schedule assumptions: do not promise external delivery dates on the normal track using the nominal 5-plus-20 working days.
3. Complete the dossier in one pass before submitting: the fast-track compresses the EDA-side clock, so the more correction rounds occur, the lower the marginal return on the priority premium.
4. Confirm the applicable clock before any change: the change scenario runs on 25 / 10 working days, which differs from registration; do not transplant the registration numbers.
5. Manage the suspension gates on working days with internal reminders: 90 working days for registration and 60 working days for changes.
6. Bring the fee terms forward: state the track and the party bearing the fees in the contract or the internal project approval, so the track is not switched at the acceptance stage.

5. Verification checklist

• □ It has been confirmed whether this project takes the normal track or the fast-track
• □ Acceptance timing has been modeled separately at 5 / 3 working days
• □ Assessment timing has been modeled separately at 20 / 7 working days
• □ Change projects have been modeled separately at 25 / 10 working days
• □ It has been confirmed that the fast-track does not change the technical documentation checklist
• □ The suspension gates (90 / 60 working days) have been entered into internal reminders
• □ The party bearing the fees for the chosen track has been fixed in the contract

Legal information verified as of 29 October 2026. The track definitions and timings listed in this article follow the current text of Sections 4.1.1 and 4.1.2 of EDREX: GL.CAMD.002 Version 2 and Section 5.2 of EDREX: GL.CAMD.003 Version 3.

• Egypt local resources: GRZAN assists manufacturers from the Chinese mainland and overseas with medical device registration, import approval and change applications before the Egyptian Drug Authority (EDA), including design of the registration applicant arrangement (importing company, local factory or scientific office), preparation for scientific committee assessment, argumentation of routes for obtaining free sale certificates from reference countries, Arabic localization of labels and instructions for use, and the establishment of vigilance systems and periodic reporting.
• Service capabilities: product attribute determination and risk classification (devices Class I–III / IVD Class A–D), registration and re-registration, applicability determination for system registration and bundled registration, three-category determination of changes, import approval and annual import plans, and support for vigilance reports and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.